on 28 Feb 2025
Last Applicant/ Owned by
Myricx Pharma Limited
London Innovation Centre, 20 Water Street, Canary Wharf
London, , E14 5GX
Serial Number
UK00004166930 filed on 28th Feb 2025
Registration Number
UK00004166930 registered on
23rd May 2025
Correspondent Information
Penningtons Manches Cooper LLP
9400 Garsington Road, Oxford Business Park
Oxford,
OX4 2HN
Pharmaceutical and biotechnological preparations; pharmaceutical and biotechnological preparations for the diagnosis and treatment of human diseases; pharmaceutical and biotechnological preparations for the diagnosis and treatment of proliferative human diseases; pharmaceutical and biotechnological preparations for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; antibody drug conjugates (ADCs); antibody drug conjugates (ADCs) for the diagnosis and treatment of human diseases; antibody drug conjugates (ADCs) for the diagnosis and treatment of proliferative human diseases; antibody drug conjugates (ADCs) for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; N-myristoyltransferases (NMT) inhibitors; N-myristoyltransferases (NMT) inhibitors for the diagnosis and treatment of human diseases; N-myristoyltransferases (NMT) inhibitors for the diagnosis and treatment of proliferative human diseases; N-myristoyltransferases (NMT) inhibitors for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging.
Scientific and biomedical research; scientific and biomedical research in the field of human diseases; scientific and biomedical research in the field of proliferative human diseases; scientific and biomedical research in the field of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; development, testing and commercialisation of pharmaceuticals and biotechnological preparations; development, testing and commercialisation of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of human diseases; development, testing and commercialisation of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of proliferative human diseases; development, testing and commercialisation of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; development, testing and commercialisation of antibody drug conjugates (ADCs) and N-myristoyltransferases (NMT) inhibitors; consultancy, advisory and information services relating to the aforesaid services.
UK00004166930
Word
Individual